Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims

Lab Test Company Did Not Conduct Data Analysis

 
• By Andrew McConaghie
  
Cassava Sciences
Cassava has seen its share price dive as the claims behind its small molecule therapy come under increasing scrutiny.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip